A New View of Cancer Diagnostics

Cernostics is a diagnostics company focused on delivering next generation cancer diagnostics and prognostics through a unique approach to tissue analysis.


Most current diagnostic approaches offer a limited view of cancer, because they fail to evaluate the tumor as a system composed of multiple interacting cell types.


Cernostics takes a tissue systems biology approach to anatomic pathology.  Its patent-protected technology platform, TissueCypher™, uniquely analyzes whole slide digital images with multiplexed fluorescence, providing greater information and accuracy than traditional subjective tissue diagnostics.  Learn more about our technology platform and how it will change the future of cancer diagnostics.


Cernostics' lead product is TissueCypher™ Barrett's Esophagus Assay.  TissueCypher™ Barrett's Esophagus Assay uses whole slide digital imaging technology to develop the most comprehensive evaluation of risk for Barrett's Esophagus patients.  It focuses on eliminating the uncertainty related to the treatment of Barrett's Esophagus patients and provides actionable information to gastroenterologists. Learn more about how TissueCypher™ Barrett's Esophagus Assay will help gastroenterologists understand which Barrett's patients are at risk for Esophageal Cancer.


Cernostics has offices in Pittsburgh and Bethlehem, PA.  Please Contact Us to meet our team.

Customer Service

Mon-Fri 9am-5pm (EST)